Immunotherapy and chronic myelomonocytic leukemia

Researchers have constantly been exploring the field of immunotherapy for diseases like chronic myelomonocytic leukemia (CMML) to improve the success rate and decrease disease burden. Currently approved treatment aim at providing the best supportive care. However, it is believed that with the development in stem cell transplantation, targeted therapies and vaccines, the patients will be able to live a healthier life. To achieve this, exhaustive knowledge of the disease presentation, risk factors, pathophysiology and diagnosis is important. The identification of the association between various genetic mutations and Myeloproliferative disorders (MPDs) has shed some light on the path to development of novel therapies. Few drugs and vaccines are under clinical trials in Phase I and II. In addition, the potential of combination therapies in improving clinical outcomes also needs to be explored. Considering all of the above, the following review is focused on providing a holistic view of CMML and the current developments in the field of immunotherapy related to this disease. Correspondence to: Dr. Nepton Sheik Khoni, MD, Ph.D., Global Allied Pharmaceutical, Center for Excellence in Research and Development, 160 Vista Oak Dr. Longwood, FL 32779, USA, Tel: 1-321-945-4283; E-mail: timothy.allen@gapsos.com


Introduction/Epidemiology
Myeloproliferative disorders (MPDs) are classified according to the most affected type of blood cells. There are four main types of MPDs, namely, Polycythemia Vera (PV), Essential thrombocythemia (ET), Myelofibrosis with Myeloid Metaplasia (MMM), and Chronic myelomonocytic leukemia (CMML).
CMML is a form of leukemia characterized by increased numbers of monocytes in the blood and bone marrow. According to the World Health Organization (WHO), CMML is classified into two subtypes based on the percentage of blast cells found in the blood and marrow: CMML-1 (less than 5 percent blasts in the blood and less than 10 percent blasts in the marrow). CMML-2 (5 to 19 percent blasts in the blood and 10 to 19 percent blasts in the marrow) [1,2]. CMML type 1 or 2, with increased number of eosinophils, are considered another specific sub-classification of CMML. CMML is rare. For example, it occurs only in four out of one million people in the United States, i.e., 1,100 cases occur each year. This disease is rare in young people. Almost 9 out of 10 cases are diagnosed in people aged 60 and above. The male to female ratio is 2:1 and the median age at presentation is 65-75 years. The disease has both myeloproliferative and myelodysplastic features [3].

Etiology/predisposing factors [3-6]
The causes of chronic MPDs remain unknown. However, an association between mutation of a particular gene known as Janus kinase 2 (JAK 2) is found in a large proportion of people with MPDs. Several risk factors associated with chronic MPDs and CMML have been identified. Some of them are:

Age and sex
PV is more common in men than in women. The condition is rarely seen in the people under the age of 40, but a few cases have been diagnosed among children. The risk of CMML increases with age. This disease is rare in those younger than 40, with most cases found in people aged 60 and above. CMML is about twice as common in men as in women.

History of cancer treatment
Prior treatment with chemotherapy seems to increase the risk of CMML. The risk of CMML after cancer chemotherapy, however, is not as high as the risk of other blood problems, such as myelodysplastic syndromes and acute myeloid leukemia.

Exposure to petrochemicals
Benzene, Toluene and ionizing radiation increases the risk of MMM.

Pathophysiology/molecular basis of CMML
Mutations such as epigenetic regulator genes, spliceosome component pathway, transcription factors and signaling regulator genes are found in about 90% of patients with CMML,

Signaling regulator gene mutations
Kosmider et al., reported variant Colony Stimulating Factor 3 Receptor (CSF3R) somatic mutations in about 4% of patients with CMML with high concordance for ASXL1 mutations [20]. Poor prognosis was seen in these patients. SET Binding Protein 1 (SETBP1) mutations are detected in about 5% of patients with CMML and are associated with a poor prognosis in patients who also have an ASXL1 mutation [20][21][22]. (DT388IL3) with potential antineoplastic activity. Upon intravenous administration, the IL3 moiety of the DT(388)IL3 fusion protein, SL-401, binds to the IL3 receptors on cells expressing the receptor. Subsequently, the DT(388) toxin moiety, which contains both translocation and catalytic domains, is transported across the cell membrane via endocytosis. Within the cytosol, the catalytic domain of the toxin catalyzes the Adenosine Di Phosphate (ADP)-ribosylation of and inactivates the translation elongation factor 2 (EF-2), inhibiting the translation during protein synthesis. IL3 may be over expressed by a variety of cancers, including blastic plasmacytoid dendritic cell neoplasm and acute myeloid leukemia (AML) ( Table 1).

Stem cell transplantation
In allogeneic stem cell transplantation, the patient receives stem cells from either a related or unrelated matched donor. It has been used to treat and sometimes cure CMML patients. However, because allogeneic stem cell transplantation is associated with a relatively high mortality risk that increases with patient age, most CMML patients are not eligible for this therapy. It is an option for a small number of patients, generally younger patients with an advanced disease, who have either failed to respond to or no longer respond to other treatment and who have an appropriate stem cell donor. Allogeneic stem cell transplant can have serious, even fatal, side effects and so is rarely used in elderly patients. Ongoing clinical trials for reduced-intensity allogeneic stem cell transplantation may prove effective and hence more patients can avail this treatment option in the future [27].

Vaccine
Non-FDA approved vaccine: Bystander Vaccine: It is a cellbased vaccine composed of irradiated tumor cells transduced with granulocyte-macrophage colony-stimulating factor (GM-CSF) and CD40-ligand (CD40L) genes. Upon administration, this vaccine may stimulate an anti-tumoral dendritic cell-mediated host immune response (Table 2).

Conclusion
The success rate in treating hematological malignancies is increasing and advancing day-by-day with the enhancing knowledge on the function of the immune system. Researchers are still challenged when exploring innate and adaptive immune systems. The identification of the JAK2-V617F mutations in chronic MPDs has stimulated a great deal of effort in screening and developing specific inhibitors for clinical use. It is certain that the next few years will bring further developments in this fast-evolving field. Immunotherapy is believed to be very promising in the field of cancer. The recent activities have increased our understanding of the tumor microenvironment, various immunotherapeutic modalities or combination therapies (like chemotherapy with immunotherapy). The effects of such modalities in combination with immunotherapy in cancer patients are still in the exploratory phase. The complete perspective of immunotherapy treatment has not been realized and/or utilized yet. In this respect, proper preclinical and clinical designs are important pillars in understanding the future of immunotherapy in treating cancer patients.